Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jul 30, 2025 (15 months ago)

BPC-157/Thymosin Beta-4 for Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

BPC-157/Thymosin Beta-4 for Injection, a) 10/10mg, b) 15/15mg, c) 15mg/15mg, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for CELIA Health, Extension Health and Medical Health Institute (MHI).

Drug: Thymosin

Recalling firm
GenoGenix LLC
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0086-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Thymosin recalls

See all
Class II · Moderate risk

Thymosin Beta - 4

Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.

Ongoing Sterility / contamination Advanced Nutriceuticals, LLC D-0140-2021
Class II · Moderate risk

Thymosin Alpha

Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.

Ongoing Sterility / contamination Advanced Nutriceuticals, LLC D-0133-2021

Other recalls by GenoGenix LLC

All 2025 recalls